Table 1.
Characteristics of Study Population
| TCGA BRCA | CBCS | CBCS Weighted %* | |
|---|---|---|---|
|
|
|
|
|
| n (%) | n (%) | (%)* | |
| Total | 1095 | 1952 | |
| Age | |||
| <50 years | 295 (26.9) | 1039 (53.2) | (34.0) |
| ≥50 years | 798 (72.9) | 913 (46.8) | (66.0) |
| Missing | 2 (0.2) | ||
| Race | |||
| Black | 183 (16.7) | 1030 (52.8) | (26.1) |
| non-Black | 816 (74.5) | 922 (47.2) | (73.9) |
| Missing | 96 (8.8) | ||
| Grade | |||
| Grade I | NA | 248 (12.7) | (16.9) |
| Grade II | NA | 511 (26.2) | (30.9) |
| Grade III | NA | 719 (36.8) | (31.1) |
| Missing | 474 (24.3) | (21.2) | |
| Stage | |||
| Stage I | 182 (16.6) | 655 (33.6) | (39.6) |
| Stage II | 619 (56.5) | 952 (48.8) | (44.7) |
| Stage III | 249 (22.7) | 255 (13.1) | (12.1) |
| Stage IV | 20 (1.8) | 67 (3.4) | (2.6) |
| Missing | 25 (2.3) | 23 (1.2) | (0.9) |
| Node Status | |||
| Negative | 516 (47.1) | 1109 (56.8) | (59.0) |
| Positive | 558 (51) | 843 (43.2) | (41.0) |
| Missing | 21 (1.9) | ||
| ER Status | |||
| Positive | 807 (73.7) | 1228 (62.9) | (71.0) |
| Negative | 239 (21.8) | 714 (36.6) | (28.6) |
| Missing | 49 (4.5) | 10 (0.5) | (0.4) |
| PAM50 | |||
| Basal | 190 (17.4) | 536 (27.5) | (20.8) |
| HER2-enriched | 82 (7.5) | 179 (9.2) | (8.2) |
| Luminal A | 566 (51.7) | 850 (43.5) | (51.4) |
| Luminal B | 217 (19.8) | 307 (15.7) | (14.8) |
| Normal-like | 40 (3.7) | 66 (3.4) | (4.0) |
| Missing | - | 14 (0.7) | (0.9) |
*
Percentages weighted for study design to approximate distribution of age and race in NC population.
TCGA= the Cancer Genome Atlas, BRCA= breast cancer, CBCS = Carolina Breast Cancer Study, ER = estrogen receptor.